Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:02 PM
Ignite Modification Date:
2025-12-24 @ 10:02 PM
NCT ID:
NCT06554535
Eligibility Criteria:
Inclusion Criteria:
1. Males or females aged ≥ 18 years.
2. Histologically or cytologically confirmed ES-SCLC (according to the Veterans Administration Lung Cancer Group \[VALG\] staging system).
3. Treatment-naïve for systemic therapy targeting ES-SCLC.
4. Patients must have at least one tumor lesion that meets the following criteria: previously untreated, accurately measurable, with a longest diameter ≥ 10 mm at baseline (for lymph nodes, short axis ≥ 15 mm), measurable by chest CT or PET-CT, as long as accurate repeat measurements can be performed.
5. ECOG performance status score of 0 or 1.
6. Expected survival ≥ 3 months.
7. Planned treatment with Serplulimab combined with platinum-based chemotherapy.
8. Patients who have previously taken or are currently taking Bayer Aspirin are allowed.
Exclusion Criteria:
1. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
2. Currently receiving other anticoagulant therapy.
3. Previous systemic anti-tumor therapy.
4. Contraindications to the use of Serplulimab, Aspirin, or chemotherapy.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06554535
Study Brief:
Protocol Section:
NCT06554535